Lv12
80 积分 2025-05-13 加入
Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors
1天前
已完结
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
5天前
已完结
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC
7天前
已完结
17 (PB003) - BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
26天前
已完结
Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights
26天前
已完结
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
28天前
已完结
50 years of Progress in Non-Small Cell Lung Cancer: A New Fellow's Guide in the Clinic
1个月前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1个月前
已完结
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
1个月前
已完结
Mechanistic study of pexidartinib-induced toxicity in human hepatic cells
1个月前
已完结
皖公网安备34019202002308
